TheraRadar
Data updated: May 26, 2026

CONTRAVE (bupropion hydrochloride)

Trial Activity: Mature 1 active trials
CNS Approved 2014-09-10

CONTRAVE is indicated for the treatment of Major Depressive Disorder; Seasonal Affective Disorder.

Source: FDA Label • NALPROPION

How CONTRAVE Works

The exact mechanism of action for bupropion is unknown, but its therapeutic effects are presumed to be mediated by noradrenergic and dopaminergic pathways. The drug functions as a relatively weak inhibitor of the neuronal uptake of the neurotransmitters norepinephrine and dopamine. Unlike some other classes of antidepressants, it does not inhibit monoamine oxidase or the reuptake of serotonin.

Development Insights

The Royal's Institute of Mental Health Research conducting 1 trials (33%)
7 indications explored (Moderate)
obesity (2 trials)
weight loss (1 trials)
weight management (1 trials)
1
Indication
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2014-09-10
Patent Cliff
2034

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
TABLET, EXTENDED RELEASE

CONTRAVE Approval History

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
14 FDA actions from 2014 to 2025
Nov 2025 SUPPL
Label · Labeling
May 2024 SUPPL
Label · Labeling
Nov 2023 SUPPL
Label · Labeling

What CONTRAVE Treats

2 indications

CONTRAVE is approved for 2 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Major Depressive Disorder
  • Seasonal Affective Disorder
Source: FDA Label

CONTRAVE Boxed Warning

SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older [see Warnings and Precautions (5.1) ]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of s...

CONTRAVE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 13 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CONTRAVE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

APLENZIN
BUPROPION HYDROBROMIDE
2 shared
BAUSCH
Shared indications:
Major Depressive DisorderSeasonal Affective Disorder
WELLBUTRIN XL
BUPROPION HYDROCHLORIDE
2 shared
BAUSCH
Shared indications:
Major Depressive DisorderSeasonal Affective Disorder
AUVELITY
BUPROPION HYDROCHLORIDE
1 shared
AXSOME
Shared indications:
📋

Clinical Trial Registry

8 trials
Trial Sponsor ID Phase Status Title
NCT06809166 2023004 Ph 4 recruiting Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity
NCT04499950 A-NEW results posted IRB00223131 Ph 2 completed Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study
NCT03431831 results posted 0763-16-FB Ph 4 completed Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic
NCT04526210 results posted ALXN1840-HV-103 Ph 1 completed Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
NCT03326128 1703346 Ph 2 terminated High Dose Bupropion for Smoking Cessation - Pilot Study
NCT01574703 CATS results posted A3051148 2011-005513-37, CATS Ph 4 completed Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
NCT01456936 EAGLES results posted A3051123 2010-022914-15, EAGLES Ph 4 completed Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
NCT01635972 9766-CL-0044 Ph 1 completed Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CONTRAVE FDA Label Details

Indications & Usage

FDA Label (PDF)

CONTRAVE is indicated for the treatment of Major Depressive Disorder; Seasonal Affective Disorder.

⚠️ BOXED WARNING

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with...

View full patent landscape →
18 OB patents · 7 families · 307 international docs across 46 countries

CONTRAVE Patents & Exclusivity

Latest Patent: Jul 2034

Patents (18 active)

US10231964 Expires Jul 2, 2034
US11998542 Expires Jul 2, 2034
US10835527 Expires Jul 2, 2034
US10828294 Expires Jul 2, 2034
US9633575 Expires Jun 25, 2033
US11139056 Expires Jun 5, 2033
US10403170 Expires Jun 5, 2033
US9248123 Expires Jan 13, 2032
US11033543 Expires Jan 10, 2031
US8916195 Expires Feb 2, 2030
US11324741 Expires May 29, 2029
US8088786 Expires Feb 3, 2029
US8722085 Expires Nov 8, 2027
US9125868 Expires Nov 8, 2027
US10307376 Expires Nov 8, 2027
US12048769 Expires Nov 8, 2027
US8318788 Expires Nov 8, 2027
US9107837 Expires Jun 4, 2027
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for CONTRAVE

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2034
  • 18 active patents

Trial Analysis

  • 3 total trials
  • Stage: Mature

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment